Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Delta 9 Cannabis Inc DLTNF

Delta 9 Cannabis Inc. is a Canada-based vertically integrated cannabis company. The Company operates through three segments: Wholesale Cannabis, Retail Cannabis and Merchandise and Devices, and Business to Business. The Company sells cannabis products through its wholesale and retail sales channels and sells its cannabis growing pods to other businesses. Its cannabis products include dried cannabis and pre-rolled joints. Its edibles and vapes include vape pens and concentrates, edibles, and drinkables. The Company, through its wholly owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical and recreational cannabis products and operates a 95,000-square-foot Health Canada licensed production facility in Winnipeg, Manitoba, Canada. It also owns and operates a chain of retail stores under the Delta 9 Cannabis Store brand. It is focused on producing and selling cannabis oils, extracts, and derivative products.


GREY:DLTNF - Post by User

Post by gnote1on Jan 13, 2021 10:19am
204 Views
Post# 32284196

Fundamental Research Dec 2020

Fundamental Research Dec 2020BUY Current Price: $0.56 Fair Value: $1.24 Risk*: 4

Revenue beat our expectations. We are revising our 2020 forecast to $58.66M (previously $52.37M), and 2021 forecast to $75.53M (previously $67.44M). • For Q3 and 2020 (9M), EBITDA was -$3.59M and $3.50M, and net losses were $5.85M 

retail cannabis sales segment (up 81% YoY) accounted for 60% of Q3 revenue.

Although it is too early to speculate whether D-Pods will gain traction, we consider D-Pods having the ability to further diversify D9’s revenue stream. For conservatism, we are not adding any potential cash flows from this product line, until we have additional details of the product’s effectiveness.

We believe D9 should focus its expansion on the other two markets due to less competition
Sask and Man
<< Previous
Bullboard Posts
Next >>